Promius Pharma has launched the Promius Promise Patient Assistance Program for eligible patients who are uninsured, or whose insurance company does not provide coverage for Isotretinoin and who otherwise meet program eligibility requirements. In April 2013, Promius introduced Zenatane (Isotretinoin Capsules USP). This new patient assistance program will be integrated into the Promius Promise Program, which is designed to help patients and healthcare providers meet treatment requirements. More than 5,000 patients are being supported by the Promius Promise program.
The Promius Promise Patient Assistance Program will potentially help Zenatane patients find alternative insurance coverage. If this is not possible, Zenatane will be provided at no cost to the eligible patient through the program. The Promius Promise Patient Assistance Program will assess patient eligibility for alternate health insurance/funding sources based on patient demographic and financial information and drug coverage information. This information is contained in a proprietary alternate payer database that includes such potential payers as Medicaid, the State Children’s Health Insurance Programs (SCHIP) and state prescription drug assistance programs, among others. Program materials will provide a summary of eligibility requirements and other restrictions.
To help initiate this program, Promius Pharma has teamed up with a leading non-profit global health organization, AmeriCares.
